Last month, a game theory expert suggested Merck & Co. focus on winning corners of the hep C market small enough that dominant players Gilead and AbbVie won't challenge its forthcoming combo treatment. And according to Merck execs, the company is already working to do just that.
Merck's July 28 second-quarter earnings call said bon voyage to Joseph Romanelli, vice president of investor relations, as he heads over to run Hong Kong and Taiwan as managing director. It also included a bit about filing plans in Japan and the outlook for China.
Merck's Ebola vaccine, in development alongside NewLink Genetics, protected 100% of patients from contracting the virus in interim results from an ongoing study, giving rise to hopes it can help prevent future outbreaks.
Digital healthcare content and marketing platform Physicians Interactive, which is a wholly owned independent subsidiary of Merck, just got bigger. Last week, it bought QuantiaMD, a popular peer-to-peer physician network, adding the key community of doctors to the digital health services it already offers.
It may not have been pretty, but Merck & Co. was able to piece together enough cost cuts and revenue surprises to exceed analysts' expectations for earnings, and push its forecast higher for the year.
Merck, maker of the pioneering immuno-oncology treatment Keytruda, is investing in the next generation of cancer therapies that harness the body's natural defenses, agreeing to pay as much as $605 million for an Israeli biotech at work in the field.
Ablynx has extended its immuno-oncology pact with Merck, boosting its potential earnings from the alliance by €4 billion ($4.4 billion) through the addition of up to 12 new programmes. But Ablynx will have to wait a while for its paydays, with just €13 million of the cash arriving as an upfront payment.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
Two recently-published market analyses paint a picture of a competitive but growing vaccines field through 2020, with the newest report from Tufts University stating the industry is on track to post $40 billion in annual sales in 5 years.
The Merck Global Health Innovation Fund invested $6 million in OpGen on the same day the microbial genetics specialist announced it will acquire AdvanDx, a maker of molecular tests for blood cultures.